Cite
HARVARD Citation
Laubach, J. et al. (2017). A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. British journal of haematology. pp. 547-560. [Online].